# Clinical trials

2 posts.

- [Silevertinib heads for a Phase 3 trial built around lung cancer that has spread to the brain](https://healthcarenews.io/news/silevertinib-phase-3-trial-egfr-lung-cancer-brain.md) (2026-11-10): Black Diamond plans a silevertinib Phase 3 trial in 2027 for EGFR lung cancer with brain metastases, after an FDA meeting and new Phase 2 data.
- [NuNerve's MND drug NUN-004 faces its first placebo-controlled test after early signs of stabilising disease](https://healthcarenews.io/news/nun-004-phase-2-trial-mnd-placebo-test.md) (2026-11-10): NuNerve's NUN-004 Phase 2 trial will test the MND drug against placebo in 75 people across six Australian sites, after a small open-label first study.